List view / Grid view
9 October 2009 | By
A pivotal attraction of qPCR technology is its apparent lack of complication; an assay consisting of the simple procedure of combining oligonucleotides, PCR mastermix buffer and nucleic acid template to produce a qPCR reaction is perceived as undemanding. This practical simplicity is complemented by the absence of any requirement for…
9 October 2009 | By Dr. Nicolas Abatzoglou, Professor and Chairman of the Department of Chemical & Biotechnological Engineering of the Université de Sherbrooke; Pierre-Philippe Lapointe-Garant, PAT Scientist and Jean-Sébastien Simard, Technical Services, both Wyeth Pharmaceuticals
Process analytical technology (PAT) initiatives are now an integral part of developmental efforts in the pharmaceutical industry. Many technical and scientific papers and even dedicated sections appear regularly in several pharmaceutical manufacturing publications. They may be part of a quality by design (QbD) project to better identify and understand critical…
9 October 2009 | By
The conference in October 2008 marked some dramatic changes for MipTec: Most notable was the policy of free registration for the conference and exhibits. This drew a record attendance for the 12 years of the conference with more than 2,300 attendees. It was so successful that free registration will be…
30 July 2009 | By
The field of oligonucleotide-based therapy experienced a revival with the discovery of RNA interference (RNAi) in 19981. RNAi is a conserved endogenous mechanism, which is triggered by double-stranded (ds) RNAs leading to target-specific inhibition of gene expression by promoting mRNA degradation or translational repression. There are two RNAi pathways that…
30 July 2009 | By
The deceptive simplicity of a typical qPCR assay is an important reason for the exponential growth in the adoption of qPCR-related technologies for both research and diagnostic applications. The only requirements for obtaining ostensibly quantitative data are a mixing of primers, DNA and a mastermix, their distribution into individual tubes…
30 July 2009 | By
We are currently on the cusp of a technology-driven revolution in the field of genomics. The rapid evolution of DNA sequencing technology is already providing researchers with the ability to generate data about genetic variation and patterns of gene expression on an unprecedented scale; within just a few years it…
30 July 2009 | By
The understanding of properties of any biological system requires a detailed and quantitative analysis of its parts and their interactions. As different processes within a system occur at defined space and time, each process holds its own optimal observation and investigation technique. One of the most powerful tools to analyse…
30 July 2009 | By
Mark Collins from Thermo Fisher Scientific, who provide analytical instruments, laboratory equipment, software, services, consumables and reagents, talks to us about current developments and future changes.
30 July 2009 | By
Going from strength to strength ELRIG are pleased to announce the 3rd Drug Discovery Symposium. This year ELRIG will be joined by the BPS (British Pharmacological Society) for the event.
In these economic times the pharmaceutical industry has expressed a renewed interest to explore ways in which to enhance the efficiency and agility of existing and future manufacturing processes. This is also true for laboratory-based operations that support forward processing and product release decisions. One function that can greatly benefit…
30 July 2009 | By
Drug transporters are membrane proteins involved in the uptake or efflux of drugs by several tissues such as the intestine, liver, kidney and brain. They can have a significant impact on the pharmacokinetics of endogenous and exogenous compounds. Also, co-administered drugs or nutrients can influence the transporter activity which may…
30 July 2009 | By Pedro E. Hernandez-Abad, Associate Director; Jun Huang, Principal PAT Scientist II and Saly Romero-Torres, Principal PAT Scientist, both Wyeth Pharmaceuticals
Boards of health like the Food and Drug Administration and European Medicines Agency and ICH guidelines Q8, Q9 and Q10, provide a framework for Quality by Design (QbD) that fully integrates drug substance and drug product development with the principles of Quality Risk Management (QRM), Process Analytical Technology (PAT) and…
29 May 2009 | By
In established economies, mental disorders account for a larger burden of disease than all cancers combined. Yet reliable, measurable, markers of such diseases (biomarkers) are not uniformly known and without them, prediction that a new drug candidate makes contact with its target is poor. This is unfortunate because the attrition…
29 May 2009 | By
The pharmaceutical industry continues to experience a high attrition rate during the latter stages of small molecule therapeutic development, most disappointingly during the late, and highly expensive stages of Phase II and Phase III trial1. If left unchecked, it is likely that this late-stage failure in drug development will only…
29 May 2009 | By
This meeting will look at recent advancements of proteomics for analysis across biological scales, i.e. from cells to tissues and organisms. The event aims to overcome the barriers and highlight the interfaces that allow us to take proteomics towards an integrative view of biology.
